At a glance
- Angiotensin II (Giapreza) is an FDA-approved drug, marketed as Giapreza, Angiotensin (first approval: December 21, 2017).
- PubMed lists 720 publications mentioning it, including 29 randomized controlled trials and 265 animal-only studies.
- ClinicalTrials.gov lists 344 registered studies testing it (56 active).
- FDA's adverse event system (FAERS) holds 754 reports mentioning it; 707 classified as serious. Reports do not prove causation.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
| Application | Product | Status | First approval | Sponsor |
|---|---|---|---|---|
| NDA209360 | GIAPREZA | Approved, marketed | December 21, 2017 | LA JOLLA PHARMA |
| ANDA216966 | ANGIOTENSIN ll ACETATE | Approved, marketed | June 3, 2025 | GLAND |
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- Perioperative management of vasoplegic syndrome in cardiac surgery: a narrative review.
- Early multimodal vasopressor strategy in septic shock: results of the TRICYCLE randomized controlled trial.
- Beyond catecholamine escalation: Receptor desensitization and endogenous vasopressor failure, and extracorporeal circuit biocompatibility after cardiopulmonary bypass-A narrative review.
- Mechanistic Assessment of Norepinephrine Therapy versus Angiotensin-II in Septic Shock (MANTRA): Study Protocol for a multicenter randomized trial.
- Proximal tubule ACE2 mediates early responses to hypertension by regulating intrarenal RAS and sodium homeostasis.
- Vasoplegia in Cardiac Surgery and Mechanical Circulatory Support: From Cardiopulmonary Bypass to Advanced Circulatory Support Devices.
- Investigating angiotensin II concentration in modulating Plasmodium falciparum infection and angiotensin receptor activation.
- Elevated Serum Renin Before Liver Transplantation Is Associated With Increased Intraoperative Vasopressor Requirements and Posttransplant Acute Kidney Injury.
- Early hemodynamic response to angiotensin II defines a prognostic phenotype in bloodstream infection-associated septic shock.
- [Vasopressors in septic shock: the old and the new].
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
- Registered
- 344
- Active
- 56
- With posted results
- 61
Conditions studied
Show 40 more studies
All 344 studies on ClinicalTrials.gov ↗
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
- Reports
- 754
- Serious
- 707
- With death outcome
- 168
Most reported reactions
Adverse event reports do not prove that the substance caused these effects. Side effects not listed here may still occur. Reaction terms are MedDRA terms as reported to FAERS.
Source: FDA FAERS (FAERS data as of July 30, 2026) · verified October 30, 2026 · API query
FDA prescribing information
Official US prescribing information. Dosing sections are intentionally not shown.
Source: DailyMed / openFDA
Change history
No changes since monitoring began on October 30, 2026.